AG Barr
ADDA solid interim performance to July from pop drinks group AG Barr in the first half, in the face of a major reorganisation of its distribution system, suggests a bumper full year lies ahead.
Profits before tax and exceptionals from the company that sells such drinks as Irn Bru, Orangina and St Clements, increased by 8.2% to £9.4 million on sales up 8.9% at £72.2 million. The interim dividend was boosted by 0.50p to 10.25p per share.
Chief executive Roger White says the diet drinks division suffered a slight year-on-year decline from which he expects it to recover in the second half. The acquisition of Strathmore mineral water has gone to plan and will eventually profit from its planned programme of investment. He also mentions that a new range of drinks for schools has been launched to comply with the regulations set down in a new Government white paper.
Wading into an energy drinks market awash with Red Bull, the sovereign of stimulatory slurps, Barr’s orange offering, Irn Bru 32, contributed five million cans in five months to a 3% progression in total Irn Bru sales, ahead of expectations. An increased marketing push in the second-half should see ever more improvement.
As the restructuring is predicted to boost operating profits £2.5m a year, house broker Investec forecasts £18.7m pre-tax for the full year, rising to £21m in 2008, producing earnings per share figures of 68.8p and 76.7p. This means the shares, last recommended by Growth Company Investor at 951.5p in February, are available for 16.8 and 15.1 times forward earnings. With Barr in all the right areas, it is still worth adding to your holding.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £225.75m
PE Forecast: 15.1
Share price: 1160p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
